EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Beyond Headache Frequency: Do Anti-CGRP Therapies Have a Disease-Modifying Role in Migraine?

Erez Magiel, Tsung-Wei Hou, Hsiangkuo Yuan

Romanian Journal of Preventive Medicine · 13.11.2026 · 4 (4) · 16

DOI: 10.3390/rjpm4040016 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Romanian Journal of Preventive Medicine, online erschienen am 13.11.2026. Verfasst von Erez Magiel und 2 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Calcitonin gene-related peptide (CGRP)-targeted therapies have transformed migraine prevention, but it remains unclear whether they change the course of migraine beyond reducing attack frequency. This narrative review asks whether current human data meet an operational framework for disease modification: clinical findings of benefit that persist beyond the expected systemic washout period and an altered subsequent trajectory, together with biological evidence of a durable change in processes implicated in progression. We searched PubMed and considered monoclonal antibodies and gepants separately because their pharmacokinetics differ. Reversion from chronic to episodic migraine and reduced medication overuse are compatible with disease modification but can also occur with any effective preventive. The benefit lasting a few months after an antibody is stopped is confounded by residual drug exposure, and lower relapse after repeated treatment cycles comes from observational cohorts open to responder selection and regression to the mean. Biomarker and imaging findings add biological plausibility but are generally small, often uncontrolled, and largely limited to on-treatment observations. No prospective trial has used chronification as a primary endpoint. Current data, therefore, do not establish disease modification. Prospective early-intervention trials, treatment-free follow-up beyond the expected washout period, and validated biomarkers are needed.

Zitieren

APA

Magiel, E., Hou, T., & Yuan, H. (2026). Beyond Headache Frequency: Do Anti-CGRP Therapies Have a Disease-Modifying Role in Migraine?. Romanian Journal of Preventive Medicine, 4(4), 16. https://doi.org/10.3390/rjpm4040016

Vancouver

Magiel E, Hou T, Yuan H. Beyond Headache Frequency: Do Anti-CGRP Therapies Have a Disease-Modifying Role in Migraine?. Romanian Journal of Preventive Medicine. 2026;4(4):16. doi:10.3390/rjpm4040016

BibTeX
@article{Magiel2026,
  author = {Magiel, Erez and Hou, Tsung-Wei and Yuan, Hsiangkuo},
  title = {Beyond Headache Frequency: Do Anti-CGRP Therapies Have a Disease-Modifying Role in Migraine?},
  journal = {Romanian Journal of Preventive Medicine},
  year = {2026},
  volume = {4},
  number = {4},
  pages = {16},
  doi = {10.3390/rjpm4040016}
}
Kostenlos starten →